2023
DOI: 10.1016/j.jpainsymman.2023.01.020
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients With Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 64 publications
0
3
0
Order By: Relevance
“…Finally, most people with cancer experience more than one symptom [ 24 ], supporting a need to assess and address symptoms concurrently. While this study focused exclusively on the symptom of pain, future research to explore spirituality-centered interventions and their role in managing co-occurring symptoms could yield a greater impact.…”
Section: Discussionmentioning
confidence: 99%
“…Finally, most people with cancer experience more than one symptom [ 24 ], supporting a need to assess and address symptoms concurrently. While this study focused exclusively on the symptom of pain, future research to explore spirituality-centered interventions and their role in managing co-occurring symptoms could yield a greater impact.…”
Section: Discussionmentioning
confidence: 99%
“…Research indicates that gynecological cancer patients undergoing chemotherapy not only experience common symptoms seen in most cancer patients, such as fatigue, sleep disturbances, peripheral neuropathy, anxiety, depression, and stigma ( 5 , 6 ), but also unique symptoms like diminished femininity, sexual dysfunction, menopausal symptoms, and decreased fertility ( 7 , 8 ). During chemotherapy, patients not only need to monitor and identify their adverse symptoms but also continuously adjust and cope with the negative impacts of chemotherapy on their well-being ( 9 , 10 ).…”
Section: Introductionmentioning
confidence: 99%
“…All participants provided informed consent and agreed to take part in the study. The study's criteria for inclusion were outlined as follows (1): Clinicopathologically confirmed tumors of the gynecologic oncology, such as cervical, endometrial, ovarian, and fallopian tube cancers (2); Age ≥ 18 years (3); Initial diagnosis (4); Undergone chemotherapy at least once (5); Clear consciousness and normal abilities in listening, speaking, reading, and writing (6); Signed informed consent and willingness to participate in the questionnaire survey. Exclusion criteria (1): Cases where family members request concealment of the illness (2); Concurrent presence of other malignant tumors (3); History of mental illness or psychological disorders.…”
mentioning
confidence: 99%